TIGIT (T cell immunoreceptor with lg and ITIM domains) is an inhibitory immunoreceptor expressed on lymphocytes in the context of cancer. TIGIT expression is highly correlated with the expression of other co-inhibitory molecules, including well known PD-1 and PD-L1. As part of the poliovirus PVR/nectin family TIGIT can enhance antitumor T cell responses in a complex signaling network engaging other cancer immunology markers like CD115 and CD112. Another marker, CD226 competes with TIGIT for CD155 binding.
TIGIT is expressed on NK cells, regulatory T cells, follicular T helper cells, memory CD4+ T cells, and CD8+ T cells. T cells together with cells in the tumor environment can suppress immune defense by up-regulating local immune inhibiting components.
Anti-TIGIT antibody clone TG1 has been developed as the first monoclonal antibody for immunhistochemical (IHC) detection of TIGIT in routine fixed FFPE human tissue specimen.
OncoDIANOVA’s vision is to provide the best antibodies against cancer immunology checkpoint biomarkers for combined use in multiplex IHC panels on human tissues. Apart from TIGIT ONCOdianova provides antibodies against other immune-checkpoint markers like CD112R and moreover against important biomarkers like Calreticulin mutations.